| Jul 30 |
Incyte drops 5 clinical drug candidates following a strategic review
|
| Jul 30 |
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
|
| Jul 30 |
Incyte Corporation (INCY) Q2 2024 Earnings Call Transcript
|
| Jul 30 |
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
|
| Jul 30 |
Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
|
| Jul 30 |
Incyte Corporation 2024 Q2 - Results - Earnings Call Presentation
|
| Jul 30 |
Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates
|
| Jul 30 |
Incyte trims cancer drug pipeline in R&D refocus
|
| Jul 30 |
Incyte: Q2 Earnings Snapshot
|
| Jul 30 |
Incyte Non-GAAP EPS of -$1.82 misses by $2.93, revenue of $1.04B beats by $30M
|
